843 related articles for article (PubMed ID: 23886836)
1. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Dubovsky JA; Beckwith KA; Natarajan G; Woyach JA; Jaglowski S; Zhong Y; Hessler JD; Liu TM; Chang BY; Larkin KM; Stefanovski MR; Chappell DL; Frissora FW; Smith LL; Smucker KA; Flynn JM; Jones JA; Andritsos LA; Maddocks K; Lehman AM; Furman R; Sharman J; Mishra A; Caligiuri MA; Satoskar AR; Buggy JJ; Muthusamy N; Johnson AJ; Byrd JC
Blood; 2013 Oct; 122(15):2539-49. PubMed ID: 23886836
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib treatment improves T cell number and function in CLL patients.
Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.
Sagiv-Barfi I; Kohrt HE; Czerwinski DK; Ng PP; Chang BY; Levy R
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):E966-72. PubMed ID: 25730880
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib-A double-edge sword in cancer and autoimmune disorders.
Kokhaei P; Jadidi-Niaragh F; Sotoodeh Jahromi A; Osterborg A; Mellstedt H; Hojjat-Farsangi M
J Drug Target; 2016; 24(5):373-85. PubMed ID: 26362595
[TBL] [Abstract][Full Text] [Related]
5. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Ryan CE; Sahaf B; Logan AC; O'Brien S; Byrd JC; Hillmen P; Brown JR; Dyer MJ; Mato AR; Keating MJ; Jaglowski S; Clow F; Rezvani AR; Styles L; Coutre SE; Miklos DB
Blood; 2016 Dec; 128(25):2899-2908. PubMed ID: 27802969
[TBL] [Abstract][Full Text] [Related]
7. Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.
Kumar A; Vardhana S; Moskowitz AJ; Porcu P; Dogan A; Dubovsky JA; Matasar MJ; Zhang Z; Younes A; Horwitz SM
Blood Adv; 2018 Apr; 2(8):871-876. PubMed ID: 29669753
[TBL] [Abstract][Full Text] [Related]
8. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.
Tillman BF; Pauff JM; Satyanarayana G; Talbott M; Warner JL
Eur J Haematol; 2018 Apr; 100(4):325-334. PubMed ID: 29285806
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.
Schutt SD; Fu J; Nguyen H; Bastian D; Heinrichs J; Wu Y; Liu C; McDonald DG; Pidala J; Yu XZ
PLoS One; 2015; 10(9):e0137641. PubMed ID: 26348529
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Bruton's tyrosine kinase and IL-2 inducible T-cell kinase suppresses both neutrophilic and eosinophilic airway inflammation in a cockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy.
Nadeem A; Ahmad SF; Al-Harbi NO; Ibrahim KE; Siddiqui N; Al-Harbi MM; Attia SM; Bakheet SA
Pharmacol Res; 2019 Oct; 148():104441. PubMed ID: 31505252
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
Jebaraj BMC; Müller A; Dheenadayalan RP; Endres S; Roessner PM; Seyfried F; Walliser C; Wist M; Qi J; Tausch E; Mertens D; Fox JA; Debatin KM; Meyer LH; Taverna P; Seiffert M; Gierschik P; Stilgenbauer S
Blood; 2022 Feb; 139(6):859-875. PubMed ID: 34662393
[TBL] [Abstract][Full Text] [Related]
12. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Honigberg LA; Smith AM; Sirisawad M; Verner E; Loury D; Chang B; Li S; Pan Z; Thamm DH; Miller RA; Buggy JJ
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13075-80. PubMed ID: 20615965
[TBL] [Abstract][Full Text] [Related]
13. Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
Hanna BS; Yazdanparast H; Demerdash Y; Roessner PM; Schulz R; Lichter P; Stilgenbauer S; Seiffert M
Haematologica; 2021 Apr; 106(4):968-977. PubMed ID: 32139435
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.
Dubovsky JA; Flynn R; Du J; Harrington BK; Zhong Y; Kaffenberger B; Yang C; Towns WH; Lehman A; Johnson AJ; Muthusamy N; Devine SM; Jaglowski S; Serody JS; Murphy WJ; Munn DH; Luznik L; Hill GR; Wong HK; MacDonald KK; Maillard I; Koreth J; Elias L; Cutler C; Soiffer RJ; Antin JH; Ritz J; Panoskaltsis-Mortari A; Byrd JC; Blazar BR
J Clin Invest; 2014 Nov; 124(11):4867-76. PubMed ID: 25271622
[TBL] [Abstract][Full Text] [Related]
15. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Advani RH; Buggy JJ; Sharman JP; Smith SM; Boyd TE; Grant B; Kolibaba KS; Furman RR; Rodriguez S; Chang BY; Sukbuntherng J; Izumi R; Hamdy A; Hedrick E; Fowler NH
J Clin Oncol; 2013 Jan; 31(1):88-94. PubMed ID: 23045577
[TBL] [Abstract][Full Text] [Related]
16. Second-generation inhibitors of Bruton tyrosine kinase.
Wu J; Liu C; Tsui ST; Liu D
J Hematol Oncol; 2016 Sep; 9(1):80. PubMed ID: 27590878
[TBL] [Abstract][Full Text] [Related]
17. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
Chen J; Kinoshita T; Sukbuntherng J; Chang BY; Elias L
Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.
Vargas L; Hamasy A; Nore BF; Smith CI
Scand J Immunol; 2013 Aug; 78(2):130-9. PubMed ID: 23672610
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.
Ren L; Campbell A; Fang H; Gautam S; Elavazhagan S; Fatehchand K; Mehta P; Stiff A; Reader BF; Mo X; Byrd JC; Carson WE; Butchar JP; Tridandapani S
J Biol Chem; 2016 Feb; 291(6):3043-52. PubMed ID: 26627823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]